Daniel Gaudet Selected Research

evinacumab

1/2022	Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.
11/2021	Evinacumab for Homozygous Familial Hypercholesterolemia. Reply.
1/2021	Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia.
12/2020	Evinacumab in Patients with Refractory Hypercholesterolemia.
1/2020	Evinacumab for Homozygous Familial Hypercholesterolemia.
11/2019	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Gaudet Research Topics

Disease

33	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 06/2004
32	Cardiovascular Diseases (Cardiovascular Disease) 07/2022 - 11/2005
18	Hypertriglyceridemia 07/2022 - 06/2002
17	Obesity 11/2016 - 05/2002
16	Coronary Artery Disease (Coronary Atherosclerosis) 10/2020 - 07/2002
15	Type 2 Diabetes Mellitus (MODY) 07/2022 - 05/2004
15	Homozygous Familial Hypercholesterolemia 01/2022 - 05/2002
13	Pancreatitis 02/2021 - 06/2010
12	Hypercholesterolemia 12/2020 - 11/2005
12	Hypertension (High Blood Pressure) 01/2019 - 05/2003
11	Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial) 01/2019 - 06/2009
10	Abdominal Obesity 01/2015 - 02/2002
9	Atherosclerosis 12/2021 - 05/2002
7	Dyslipidemias (Dyslipidemia) 07/2022 - 03/2010
7	Inborn Genetic Diseases (Disease, Hereditary) 12/2019 - 03/2010
6	Xanthomatosis (Xanthoma) 06/2020 - 03/2005
6	Glucose Intolerance 04/2014 - 05/2002
6	Insulin Resistance 04/2013 - 02/2005
6	Hypertriglyceridemic Waist 08/2012 - 07/2002
5	Inflammation (Inflammations) 01/2022 - 01/2011
5	Injection Site Reaction 01/2021 - 03/2010
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2020 - 01/2004
4	Body Weight (Weight, Body) 12/2020 - 12/2004
4	Hyperlipoproteinemia Type III (Broad Beta Disease) 01/2015 - 12/2010
3	Non-alcoholic Fatty Liver Disease 02/2021 - 12/2015
3	COVID-19 01/2021 - 01/2021
3	Rare Diseases (Rare Disease) 11/2019 - 02/2015
3	Muscular Diseases (Myopathy) 01/2019 - 02/2012
3	Costello Syndrome 07/2018 - 02/2015
3	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2017 - 10/2010
3	Overweight 06/2016 - 01/2011
3	Hyperinsulinism (Hyperinsulinemia) 08/2012 - 02/2002
2	Myocardial Infarction 12/2021 - 08/2007
2	Coronary Disease (Coronary Heart Disease) 01/2021 - 01/2020
2	Myalgia 01/2019 - 11/2015
2	Hypoalphalipoproteinemias (Hypoalphalipoproteinemia) 01/2018 - 12/2015
2	Diabetes Mellitus 09/2013 - 02/2005
2	Metabolic Diseases (Metabolic Disease) 09/2013 - 07/2006

Drug/Important Bio-Agent (IBA)

32	oxidized low density lipoproteinIBA 01/2022 - 02/2002
31	LDL CholesterolIBA 01/2022 - 04/2008
29	LipidsIBA 01/2022 - 06/2002
29	Triglycerides (Triacylglycerol)IBA 01/2022 - 02/2002
21	HDL CholesterolIBA 07/2022 - 02/2002
19	Lipoproteins (Lipoprotein)IBA 07/2022 - 02/2002
19	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 05/2002
14	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 07/2002
11	ApolipoproteinsIBA 07/2022 - 01/2004
9	CholesterolIBA 11/2020 - 02/2002
8	Apolipoproteins B (ApoB)IBA 07/2022 - 02/2002
8	LDL Receptors (LDL Receptor)IBA 01/2022 - 01/2006
8	alirocumabIBA 01/2022 - 07/2012
7	Biomarkers (Surrogate Marker)IBA 07/2022 - 02/2005
7	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022 - 02/2002
7	HDL LipoproteinsIBA 10/2020 - 06/2002
7	Ezetimibe (Zetia)FDA Link 12/2019 - 05/2002
7	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2019 - 06/2002
6	Monoclonal AntibodiesIBA 01/2022 - 09/2014
6	evinacumabIBA 01/2022 - 11/2019
6	Proteins (Proteins, Gene)FDA Link 11/2019 - 05/2004
5	BMS201038IBA 01/2022 - 01/2013
5	microsomal triglyceride transfer proteinIBA 01/2022 - 02/2002
5	evolocumabIBA 01/2021 - 01/2015
5	Rosuvastatin Calcium (Crestor)FDA Link 01/2018 - 09/2013
4	Proprotein Convertase 9IBA 01/2022 - 09/2018
4	C-Reactive ProteinIBA 01/2019 - 08/2007
4	Lipoprotein(a)IBA 04/2016 - 11/2012
4	Insulin (Novolin)FDA Link 04/2013 - 06/2002
3	Messenger RNA (mRNA)IBA 01/2022 - 04/2014
3	ISIS 304801IBA 01/2021 - 12/2014
3	Fibric Acids (Fibrates)IBA 06/2020 - 12/2010
3	Pharmaceutical PreparationsIBA 01/2020 - 06/2007
3	ChylomicronsIBA 01/2020 - 01/2013
3	LeptinIBA 01/2016 - 05/2003
3	mipomersenIBA 12/2015 - 03/2010
3	Apolipoproteins E (ApoE)IBA 01/2015 - 12/2010
3	Apolipoprotein E2IBA 01/2015 - 06/2002
3	AdiponectinIBA 02/2012 - 02/2005
2	Apolipoprotein C-IIIIBA 01/2022 - 07/2015
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 02/2007
2	Biological ProductsIBA 01/2021 - 11/2016
2	CER-001IBA 10/2020 - 05/2015
2	Glycerol (Glycerine)FDA LinkGeneric 06/2020 - 02/2005
2	VLDL LipoproteinsIBA 01/2020 - 01/2015
2	AngiopoietinsIBA 01/2020 - 11/2019
2	VLDL CholesterolIBA 12/2019 - 01/2015
2	Apolipoprotein C-II (ApoC2)IBA 07/2018 - 01/2017
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2018 - 06/2016
2	Cholesterol Ester Transfer ProteinsIBA 01/2018 - 06/2004
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 02/2014
2	Poly TIBA 01/2018 - 06/2016
2	Antihypertensive Agents (Antihypertensives)IBA 06/2016 - 04/2015
2	Fenofibrate (CiL)FDA LinkGeneric 01/2016 - 01/2004
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 05/2015 - 02/2007
2	Oxidoreductases (Dehydrogenase)IBA 08/2012 - 02/2012
2	Adenosine Triphosphate (ATP)IBA 08/2012 - 01/2012
2	Lipase (Acid Lipase)FDA Link 08/2012 - 01/2003

Therapy/Procedure

24	Therapeutics 01/2022 - 05/2002
4	Precision Medicine 01/2019 - 01/2014
3	Fat-Restricted Diet (Diet, Fat Restricted) 05/2020 - 06/2010
3	Blood Component Removal (Apheresis) 01/2019 - 05/2002